Lipoic Acid Pellets Gastroresistant Coating Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lipoic acid formulations face challenges with bioavailability, production process, and stability due to its poor water solubility and instability under environmental conditions, which existing pharmaceutical formulations have not adequately addressed.
Innovation Solution
Development of lipoic acid formulations using inert cores coated with a polymeric insulating layer and an outer gastroresistant polymeric membrane, ensuring high reproducibility and stability, and allowing for controlled release profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If lipoic acid is simply mixed with excipients in tablets or capsules, then the formulation is easy to manufacture, but the bioavailability and stability of lipoic acid are poor
Solution Approach 1:
The lipoic acid is segmented into particles of specific size ranges (150-450 microns) and further divided into coated and uncoated portions. The coated particles (50-70% by weight) are blended with excipients and compressed into tablets, while uncoated particles are encapsulated in capsules. This segmentation allows optimization of bioavailability through controlled release mechanisms while maintaining manufacturing feasibility.
Solution Approach 2:
Methacrylate ester copolymers are used as intermediary coating materials on lipoic acid particles. This coating layer acts as a mediator that controls the release of lipoic acid, protecting it from degradation while enabling sustained release over 4+ hours. The copolymer coating resolves the contradiction by providing both stability protection and controlled bioavailability enhancement.
2Reliability
If lipoic acid particles are coated with methacrylate ester copolymers for controlled release, then the bioavailability is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The manufacturing process is segmented into distinct streams: one for coating particles (which are then tableted) and another for uncoated particles (which are encapsulated). This segmentation allows the complex coating process to be applied only where necessary for bioavailability optimization, while simpler processes are used elsewhere, balancing overall manufacturing complexity with therapeutic benefit.
Solution Approach 2:
The invention specifies precise particle size parameters (150-450 microns) and coating composition parameters (methacrylate ester copolymers with specific ratios). By controlling these parameters, the coating process becomes more predictable and manufacturable, reducing the complexity burden while maintaining the bioavailability benefits.
3Device complexity
If lipoic acid is used in acid form in tablets, then the formulation is simple, but the bioavailability is reduced compared to sodium salt forms
Solution Approach 1:
The invention changes the physical parameters of the lipoic acid by controlling particle size (150-450 microns) and applying polymer coatings, rather than changing the chemical form to sodium salt. This parameter change approach maintains the simple acid form while achieving improved bioavailability through physical modification and controlled release mechanisms.
Solution Approach 2:
The methacrylate ester copolymer coating acts as an intermediary that enhances the bioavailability of lipoic acid in its acid form. This coating mediator protects the acid form from degradation and controls its release profile, achieving bioavailability levels comparable to or exceeding sodium salt formulations without the complexity of salt conversion.
4Speed
If lipoic acid is released quickly to achieve therapeutic levels, then the onset of action is fast, but the duration of action is limited to less than 4 hours
Solution Approach 1:
The controlled release formulation implements periodic action through sustained release mechanisms. The methacrylate ester copolymer coating releases lipoic acid in a controlled periodic manner over 4 or more hours, maintaining therapeutic levels throughout the dosing interval. This periodic release pattern ensures both adequate onset and prolonged duration of action.
Solution Approach 2:
The formulation ensures continuity of useful action by maintaining therapeutic levels of lipoic acid for 4 or more hours through controlled release. The copolymer coating provides a continuous release profile that prevents abrupt drops in concentration, ensuring uninterrupted therapeutic effect throughout the dosing period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described formulation enhances bioavailability and stability of lipoic acid, maintaining its chemical integrity and providing a controlled release profile, thereby overcoming the limitations of previous formulations.
Implementation Method 1
allowing for controlled release profiles
Implementation Method 2
inert cores externally coated with lipoic acid. The so obtained active cores are coated with a first layer of insulating polymeric material and then with a polymeric coat that is insoluble at the gastric pH
Implementation Method 3
a polymeric coat that is insoluble at the gastric pH
Data Source
AI summary
Lipoic acid pellets are described, obtained from inert cores externally coated with lipoic acid. The so obtained active cores are coated with a first layer of insulating polymeric material and then with a polymeric coat that is insoluble at the gastric pH. Pellet are then formulated pharmaceutically, for instance in jelly capsules or controlled release capsules or as oral suspensions, dispersible powders, sachets, etc.